论文部分内容阅读
美国MetaPhors制药公司已完成一种小分子超氧化物歧化酶（SOD）模拟物M40403的首次临床试验,并报道,经静脉注射给药,未见该药的剂量
MetaPhors Pharmaceuticals, Inc., the United States, has completed its first clinical trial of a small molecule superoxide dismutase (SOD) mimetic M40403 and reported that no dose of this drug was administered by intravenous injection